Antitumor Activity Of Tak-285, An Investigational,Non-Pgp Substrate Her2/Egfr Kinase Inhibitor, In Cultured Tumor Cells, Mouse And Rat Xenograft Tumors, And In An Her2-Positive Brain Metastasis Model

Journal of Cancer

Volumn 4, Issue 7, 2013, Pages 557-565

  Nakayama, Akiko ^a   Takagi, Shinji ^a   Yusa, Tadashi ^a   Yaguchi, Masahiro ^a   Hayashi, Akira ^a   Tamura, Toshiya ^a   Kawakita, Youichi ^a   Ishikawa, Tomoyasu ^a   Ohta, Yoshikazu ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Brain Metastases; Dual Her2 Egfr Kinase Inhibitor; Lapatinib; Murine Xenografts; Tak 285

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; LUCIFERASE; TAK 285; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BRAIN METASTASIS; BREAST CANCER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84883045013     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6689     Document Type: Article

References (25)

1. Santarelli JG, Sarkissian V, Hou LC, et al. Molecular events of brain metastasis. Neurosurg Focus 2007; 22(3): E1.
2. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011; 11(5): 352-63.
3. Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: A treatment challenge. Oncologist 2008; 13(7): 739-50.
4. Sun H, Dai H, Shaik N, et al. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 2003; 55(1): 83-105.
5. Lin JH. How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today (Barc) 2004; 40(1): 5-22.
6. Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005; 7(6): R1028-35.
7. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5(5): 341-54.
8. Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007; 12(7): 766-73.
9. Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)et hyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008; 36(4): 695-701.
10. Polli JW, Olson KL, Chism JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)et hyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 2009; 37(2): 439-42.
11. Ishikawa T, Seto M, Banno H, et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem 2011; 54(23): 8030-50.
12. Aertgeerts K, Skene R, Yano J, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 2011; 286(21): 18756-65.
13. LoRusso P, Chiorean EG, Heath E, et al. Phase 1 Dose-Escalation Study of the Investigational HER2/EGFR Inhibitor TAK-285 in Patients with Advanced Cancer. Cancer Research 2011; 70: P3-14-20.
14. Chiorean EG, Sausville EA, Heath EI, et al. Phase I study of TAK-285, an investigational HER2/EGFR inhibitor, in patients (pts) with advanced cancer: Updated results and assessment of human CSF distribution. J Clin Oncol 2011; 29 (Suppl 15): Abstract2538.
15. Tamura T, Takagi S, Horikoshi K, et al. Combined antitumor efficacies of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor, with other anticancer drugs. Eur J Cancer Suppl 2008; 6(12, Abstract 314): 100-1.
16. Wu JT, Liao M, Gordon J, et al. TAK-285, a Novel HER2/EGFR Inhibitor, Penetrates the CNS in Rats with an Intact Blood Brain Barrier (BBB). Cancer Research 2009; 69 (Suppl 3): Abstract5098.
17. Erdo F, Gordon J, Wu JT, Sziráki I. Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats. Brain Res Bull 2012; 87(4-5): 413-9.
18. Mcclure MS, Osterhout MH, Roschangar F, et al. A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts. PCT Int; WO 02/02552. 2002.
19. Tsou HR, Overbeek-Klumpers EG, Hallett WA, et al. Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally AcActive, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor- 2 Kinase Activity. J Med Chem 2005; 48(4): 1107-31.
20. Harker WG, MacKintosh FR, Sikic BI. Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res 1983; 43(10): 4943-50.
21. Dunnett CW, Tamhane AC. Some new multiple-test procedures for dose finding. J Biopharm Stat 1998; 8(3): 353-66.
22. GlaxoSmithKline. Lapatinib (Tykerb®) [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline. 2012.
23. Palmieri D, Bronder JL, Herring JM, et al. Her-2 Overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67(9): 4190-98.
24. Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459(7249): 1005-09.
25. Downey T. Analysis of a multifactor microarray study using Partek genomics solution. Methods Enzymol 2006; 411: 256-70.